Mark A Socinski1. Show Affiliations » 1. Co-Leader, UPCI Lung Cancer Program University of Pittsburgh Medical Center Pittsburgh, PA.
Abstract
Entities: Disease
Mesh: See more » Antibodies, Monoclonal/immunologyAntibodies, Monoclonal/therapeutic useAntineoplastic Agents/immunologyAntineoplastic Agents/therapeutic useCarcinoma, Non-Small-Cell Lung/immunologyCarcinoma, Non-Small-Cell Lung/therapyHumansImmunotherapy/methodsImmunotherapy/trendsLung Neoplasms/immunologyLung Neoplasms/therapyLymphocyte Activation/immunologyNivolumabProgrammed Cell Death 1 Receptor/antagonists & inhibitorsProgrammed Cell Death 1 Receptor/immunologySignal Transduction/immunologyT-Lymphocytes/immunology
Substances: See more » Antibodies, MonoclonalAntineoplastic AgentsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorNivolumab
Year: 2015 PMID: 26477469 DOI: 10.1053/j.seminoncol.2015.09.018
Source DB: PubMed Journal: Semin Oncol ISSN: 0093-7754 Impact factor: 4.929